Skip to main content
Premium Trial:

Request an Annual Quote

US Supreme Court Declines to Hear CareDx Organ Transplant Patent Infringement Case

This article has been updated to include a ruling that occurred after that awarding CareDx damages related to false advertising claims.

NEW YORK – The US Supreme Court on Monday declined to hear a patent infringement lawsuit brought by CareDx against Natera and Eurofins Viracor over patents related to cell-free DNA analysis for noninvasive monitoring of organ transplant rejection.

CareDx had announced earlier that it was considering appealing the case to the Supreme Court after two separate federal appeals court rulings that found CareDx's patents invalid for the purpose of claiming patent-ineligible subject matter.

In a separate lawsuit that CareDx brought against Natera, a jury last year awarded CareDx $44.9 million in compensatory and punitive damages related to false advertising and unfair competition. This decision was later voided when the District Court for the District of Delaware found Natera not guilty of unfair competition and ruled that CareDx was not entitled to damages related to that claim.

Although the Supreme Court declined to hear the case, Justice Brett Kavanaugh wrote in the order that he would have granted CareDx's petition.